360 related articles for article (PubMed ID: 22448975)
21. Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation.
Rubenstein LA; Zauhar RJ; Lanzara RG
J Mol Graph Model; 2006 Dec; 25(4):396-409. PubMed ID: 16574446
[TBL] [Abstract][Full Text] [Related]
22. Structural properties of orexins for activation of their receptors.
Lang M; Bufe B; De Pol S; Reiser O; Meyerhof W; Beck-Sickinger AG
J Pept Sci; 2006 Apr; 12(4):258-66. PubMed ID: 16138386
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.
Malherbe P; Borroni E; Gobbi L; Knust H; Nettekoven M; Pinard E; Roche O; Rogers-Evans M; Wettstein JG; Moreau JL
Br J Pharmacol; 2009 Apr; 156(8):1326-41. PubMed ID: 19751316
[TBL] [Abstract][Full Text] [Related]
24. Orexins modulate the growth of cultured rat adrenocortical cells, acting through type 1 and type 2 receptors coupled to the MAPK p42/p44- and p38-dependent cascades.
Spinazzi R; Ziolkowska A; Neri G; Nowak M; Rebuffat P; Nussdorfer GG; Andreis PG; Malendowicz LK
Int J Mol Med; 2005 May; 15(5):847-52. PubMed ID: 15806308
[TBL] [Abstract][Full Text] [Related]
25. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors.
Bhattacharya S; Hall SE; Vaidehi N
J Mol Biol; 2008 Oct; 382(2):539-55. PubMed ID: 18638482
[TBL] [Abstract][Full Text] [Related]
26. Structure-function relationships of the human bitter taste receptor hTAS2R1: insights from molecular modeling studies.
Dai W; You Z; Zhou H; Zhang J; Hu Y
J Recept Signal Transduct Res; 2011 Jun; 31(3):229-40. PubMed ID: 21619450
[TBL] [Abstract][Full Text] [Related]
27. Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders.
Bonifazi A; Del Bello F; Giorgioni G; Piergentili A; Saab E; Botticelli L; Cifani C; Micioni Di Bonaventura E; Micioni Di Bonaventura MV; Quaglia W
Med Res Rev; 2023 Sep; 43(5):1607-1667. PubMed ID: 37036052
[TBL] [Abstract][Full Text] [Related]
28. Antiallodynic effects of intrathecal orexins in a rat model of postoperative pain.
Cheng JK; Chou RC; Hwang LL; Chiou LC
J Pharmacol Exp Ther; 2003 Dec; 307(3):1065-71. PubMed ID: 14551290
[TBL] [Abstract][Full Text] [Related]
29. The orexin OX(1) receptor exists predominantly as a homodimer in the basal state: potential regulation of receptor organization by both agonist and antagonist ligands.
Xu TR; Ward RJ; Pediani JD; Milligan G
Biochem J; 2011 Oct; 439(1):171-83. PubMed ID: 21770891
[TBL] [Abstract][Full Text] [Related]
30. Modeling GPCR active state conformations: the β(2)-adrenergic receptor.
Simpson LM; Wall ID; Blaney FE; Reynolds CA
Proteins; 2011 May; 79(5):1441-57. PubMed ID: 21337626
[TBL] [Abstract][Full Text] [Related]
31. Integrating Pharmacophore into Membrane Molecular Dynamics Simulations to Improve Homology Modeling of G Protein-coupled Receptors with Ligand Selectivity: A2A Adenosine Receptor as an Example.
Zeng L; Guan M; Jin H; Liu Z; Zhang L
Chem Biol Drug Des; 2015 Dec; 86(6):1438-50. PubMed ID: 26072970
[TBL] [Abstract][Full Text] [Related]
32. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5.
Andrews G; Jones C; Wreggett KA
Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736
[TBL] [Abstract][Full Text] [Related]
33. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
Roecker AJ; Mercer SP; Schreier JD; Cox CD; Fraley ME; Steen JT; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
ChemMedChem; 2014 Feb; 9(2):311-22. PubMed ID: 24376006
[TBL] [Abstract][Full Text] [Related]
34. Activation of the ghrelin receptor is described by a privileged collective motion: a model for constitutive and agonist-induced activation of a sub-class A G-protein coupled receptor (GPCR).
Floquet N; M'Kadmi C; Perahia D; Gagne D; Bergé G; Marie J; Banères JL; Galleyrand JC; Fehrentz JA; Martinez J
J Mol Biol; 2010 Jan; 395(4):769-84. PubMed ID: 19782690
[TBL] [Abstract][Full Text] [Related]
35. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding.
Zhao MM; Hwa J; Perez DM
Mol Pharmacol; 1996 Nov; 50(5):1118-26. PubMed ID: 8913343
[TBL] [Abstract][Full Text] [Related]
36. [Possible mechanisms for orexin effects on the functioning of the hippocampus and spatial learning (analytical review)].
Sil'kis IG
Zh Vyssh Nerv Deiat Im I P Pavlova; 2012; 62(4):389-400. PubMed ID: 23035556
[TBL] [Abstract][Full Text] [Related]
37. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.
Yin J; Babaoglu K; Brautigam CA; Clark L; Shao Z; Scheuermann TH; Harrell CM; Gotter AL; Roecker AJ; Winrow CJ; Renger JJ; Coleman PJ; Rosenbaum DM
Nat Struct Mol Biol; 2016 Apr; 23(4):293-9. PubMed ID: 26950369
[TBL] [Abstract][Full Text] [Related]
38. Orexins depolarize rostral ventrolateral medulla neurons and increase arterial pressure and heart rate in rats mainly via orexin 2 receptors.
Huang SC; Dai YW; Lee YH; Chiou LC; Hwang LL
J Pharmacol Exp Ther; 2010 Aug; 334(2):522-9. PubMed ID: 20494957
[TBL] [Abstract][Full Text] [Related]
39. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
40. Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists.
Faedo S; Perdonà E; Antolini M; di Fabio R; Merlo Pich E; Corsi M
Eur J Pharmacol; 2012 Oct; 692(1-3):1-9. PubMed ID: 22796453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
